NRx Subsidiary HOPE Therapeutics Opens Palm Beach Clinic for Rapid Depression and PTSD Treatment

Event summary

  • HOPE Therapeutics, an NRx subsidiary, opened a Palm Beach clinic offering one-day treatment for depression and PTSD using TMS, ketamine, and hyperbaric oxygen therapy.
  • Published results show an 87% clinical response rate for treatment-resistant depression with the clinic's protocol.
  • The clinic is the latest addition to HOPE's growing network and features a partnership with neurocare AG for advanced non-invasive treatments.
  • HOPE claims to be the first network in Florida to offer the AMPA One Day (ONE-D) treatment combining TMS, D-cycloserine, and lisdexamfetamine.

The big picture

HOPE Therapeutics' Palm Beach clinic opening represents a strategic push into rapid, non-invasive mental health treatments, aligning with broader industry shifts toward neuroplastic therapies. The clinic's combination of TMS, ketamine, and hyperbaric oxygen therapy positions NRx to compete in the growing market for treatment-resistant depression and PTSD solutions. The partnership with neurocare AG suggests a focus on leveraging European advancements in non-invasive psychiatric care.

What we're watching

Clinical Efficacy
Whether the 87% clinical response rate observed in published studies will translate to real-world patient outcomes at the new Palm Beach location.
Market Expansion
The pace at which HOPE Therapeutics can scale its clinic network and integrate neurocare AG's technologies across additional locations.
Regulatory Dynamics
How NRx Pharmaceuticals' ongoing regulatory filings for NRX-100 and NRX-101 may impact HOPE Therapeutics' treatment offerings and market positioning.